Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans.
The presence of nutrients in the small intestine slows gastric emptying and suppresses appetite and food intake; these effects are partly mediated by the release of gut hormones, including CCK. We investigated the hypothesis that the modulation of antropyloroduodenal motility, suppression of appetite, and stimulation of CCK and glucagon-like peptide-1 secretion by intraduodenal fat are dependent on triglyceride hydrolysis by lipase. Sixteen healthy, young, lean men were studied twice in double-blind, randomized, crossover fashion. Ratings for appetite-related sensations, antropyloroduodenal motility, and plasma CCK and glucagon-like peptide-1 concentrations were measured during a 120-min duodenal infusion of a triglyceride emulsion (2.8 kcal/min) on one day with, on the other day without, 120 mg tetrahydrolipstatin, a potent lipase inhibitor. Immediately after the duodenal fat infusion, food intake at a buffet lunch was quantified. Lipase inhibition with tetrahydrolipstatin was associated with reductions in tonic and phasic pyloric pressures, increased numbers of isolated antral and duodenal pressure waves, and stimulation of antropyloroduodenal pressure-wave sequences (all P < 0.05). Scores for prospective consumption and food intake at lunch were greater, and nausea scores were slightly less, and the rises in plasma CCK and glucagon-like peptide-1 were abolished (all P < 0.05). In conclusion, lipase inhibition attenuates the effects of duodenal fat on antropyloroduodenal motility, appetite, and CCK and glucagon-like peptide-1 secretion.
Feinle
Christine
C
University of Adelaide Department of Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. christine.feinle@adelaide.edu.au
O'Donovan
Deirdre
D
Doran
Selena
S
Andrews
Jane M
JM
Wishart
Judith
J
Chapman
Ian
I
Horowitz
Michael
M
D000328:Adult; D001066:Appetite / Q000187:drug effects*; D002766:Cholecystokinin / Q000097:blood / Q000378:metabolism*; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology*; D004311:Double-Blind Method; D004386:Duodenum / Q000187:drug effects*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D008049:Lipase / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D010446:Peptide Fragments / Q000097:blood / Q000378:metabolism*; D011498:Protein Precursors / Q000097:blood / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D004041:Dietary Fats; D010446:Peptide Fragments; D011498:Protein Precursors; D014280:Triglycerides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D002766:Cholecystokinin; D008049:Lipase